\
&
Contact us
\
&
Contact us
This was 4 years ago
LocationOnline
ProgrammesThough strictly speaking not related to Horizon 2020 or Horizon Europe, this event could turn out to be one of the best brokerage events you'll see in 2021 in the field of Artificial Intelligence.
This event is the stepping stone to jump-start the preparations for projects that will be submitted for the Eureka Clusters AI Call 2021. This is a transnational call, meaning that every organisation has to requiest funding at their local innovation agency - in Flanders this is VLAIO. More information on the VLAIO website.
This means of (Flemish R&D) funding can be interesting for you. But even when that is not the case, you could consider participating as this is the place to be, to meet existing and new R&D players in the field of Artificial Intelligence this spring.
Next to the Brokerage event, an efficient online tool set has been created for you to shape project idea(s) and to help you identify potential project partners to build consortia.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
